These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20888107)

  • 1. The value of more information: a commentary on Stewart et al.
    Lillard DR
    Soc Sci Med; 2010 Dec; 71(11):1910-2; discussion 1912-3. PubMed ID: 20888107
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary on Vemer et al. (2010): when is smoking cessation really cost-effective?
    Salize HJ
    Addiction; 2010 Jun; 105(6):1098-9. PubMed ID: 20659064
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary on Herd & Borland (2009) and Herd et al. (2009): illuminating the course and dynamics of smoking cessation.
    Shiffman S
    Addiction; 2009 Dec; 104(12):2100-1. PubMed ID: 19922575
    [No Abstract]   [Full Text] [Related]  

  • 4. Considering race/ethnicity and socio-economic status in randomized controlled trials. A commentary on Frampton et al.'s systematic review generalizing trial findings and tackling health disparities in asthma research.
    Kreatsoulas C; Anand S
    Soc Sci Med; 2009 Oct; 69(8):1155-6. PubMed ID: 19640625
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomization, permuted blocks, masking, allocation concealment, and selection bias in the Tobacco Quit Line Study.
    Berger VW
    Contemp Clin Trials; 2010 May; 31(3):201. PubMed ID: 20219696
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to commentary on "Blood lead, cadmium, and mercury concentrations in the Korean population" by Minoia et al.
    Lee JT; Paek D
    Environ Res; 2010 Jul; 110(5):533-4. PubMed ID: 20399423
    [No Abstract]   [Full Text] [Related]  

  • 7. What's needed for personalized therapy in smoking cessation.
    Epstein RS
    Clin Pharmacol Ther; 2008 Sep; 84(3):309-10. PubMed ID: 18714320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of sampling error on results of inverse projection: an empirical study].
    Montanari GE; Bussini O
    Boll Demogr Stor; 1996; (24-25):131-44. PubMed ID: 12348617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value to smokers of improved cessation products: evidence from a willingness-to-pay survey.
    Busch S; Falba T; Duchovny N; Jofre-Bonet M; O'Malley S; Sindelar J
    Nicotine Tob Res; 2004 Aug; 6(4):631-9. PubMed ID: 15370159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smoking treatment interventions and policies to promote their use: a critical review.
    Friend K; Levy DT
    Nicotine Tob Res; 2001 Nov; 3(4):299-310. PubMed ID: 11694197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research methods from social science can contribute much to the health sciences.
    Wensing M
    J Clin Epidemiol; 2008 Jun; 61(6):519-20. PubMed ID: 18471653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow.
    Boyd KA; Briggs AH
    Addiction; 2009 Feb; 104(2):317-25. PubMed ID: 19149829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation.
    Nielsen K; Fiore MC
    Prev Med; 2000 Mar; 30(3):209-16. PubMed ID: 10684744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-benefit analysis of smoking cessation programs during the first trimester of pregnancy for the prevention of low birthweight.
    Hueston WJ; Mainous AG; Farrell JB
    J Fam Pract; 1994 Oct; 39(4):353-7. PubMed ID: 7931114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database.
    Olsen KR; Bilde L; Juhl HH; Kjaer NT; Mosbech H; Evald T; Rasmussen M; Hiladakis H
    Eur J Health Econ; 2006 Dec; 7(4):255-64. PubMed ID: 16816946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of smoking cessation modalities: comparing apples with oranges?
    Mudde AN; de Vries H; Strecher VJ
    Prev Med; 1996; 25(6):708-16. PubMed ID: 8936573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-benefit analysis involving addictive goods: contingent valuation to estimate willingness-to-pay for smoking cessation.
    Weimer DL; Vining AR; Thomas RK
    Health Econ; 2009 Feb; 18(2):181-202. PubMed ID: 18566968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
    Bolin K; Mörk AC; Willers S; Lindgren B
    Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
    Thavorn K; Chaiyakunapruk N
    Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial to promote pharmacotherapy use and smoking cessation in a Medicaid population (United States).
    Murphy JM; Mahoney MC; Cummings KM; Hyland AJ; Lawvere S
    Cancer Causes Control; 2005 May; 16(4):373-82. PubMed ID: 15953979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.